The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation

N. Navarro-Alvarez, J. A. Shah, A. Zhu, J. Ligocka, H. Yeh, N. Elias, I. Rosales, R. Colvin, A. B. Cosimi, J. F. Markmann, M. Hertl, D. H. Sachs, P. A. Vagefi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We sought to determine the effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors. After LXT, baboons received no coagulation factors (historical control, n = 1), bolus administration of a human prothrombin concentrate complex (hPCC; 2.5 mL/kg, n = 2), continuous infusion of hPCC (1.0 mL/h, n = 1) or continuous infusion of human recombinant factor VIIa (1 µg/kg per hour, n = 3). The historical control recipient demonstrated persistent thrombocytopenia despite platelet administration after transplant, along with widespread thrombotic microangiopathy (TMA). In contrast, platelet levels were maintained in bolus hPCC recipients; however, these animals quickly developed large-vessel thrombosis and TMA, leading to graft failure with shortened survival. Recipients of continuous coagulation factor administration experienced either stabilization or an increase in their circulating platelets with escalating doses. Furthermore, transfusion requirements were decreased, and hepatic TMA was noticeably absent in recipients of continuous coagulation factor infusions compared with the historical control and bolus hPCC recipients. This effect was most profound with a continuous, escalating dose of factor VIIa. Further studies are warranted because this regimen may allow for prolonged survival following LXT.

Original languageEnglish (US)
Pages (from-to)1715-1725
Number of pages11
JournalAmerican Journal of Transplantation
Volume16
Issue number6
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Heterologous Transplantation
Blood Coagulation Factors
Papio
Thrombotic Microangiopathies
Swine
Blood Platelets
Liver
Transplants
Factor VIIa
Survival
Thrombocytopenia
Thrombosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation. / Navarro-Alvarez, N.; Shah, J. A.; Zhu, A.; Ligocka, J.; Yeh, H.; Elias, N.; Rosales, I.; Colvin, R.; Cosimi, A. B.; Markmann, J. F.; Hertl, M.; Sachs, D. H.; Vagefi, P. A.

In: American Journal of Transplantation, Vol. 16, No. 6, 01.01.2016, p. 1715-1725.

Research output: Contribution to journalArticle

Navarro-Alvarez, N, Shah, JA, Zhu, A, Ligocka, J, Yeh, H, Elias, N, Rosales, I, Colvin, R, Cosimi, AB, Markmann, JF, Hertl, M, Sachs, DH & Vagefi, PA 2016, 'The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation', American Journal of Transplantation, vol. 16, no. 6, pp. 1715-1725. https://doi.org/10.1111/ajt.13647
Navarro-Alvarez, N. ; Shah, J. A. ; Zhu, A. ; Ligocka, J. ; Yeh, H. ; Elias, N. ; Rosales, I. ; Colvin, R. ; Cosimi, A. B. ; Markmann, J. F. ; Hertl, M. ; Sachs, D. H. ; Vagefi, P. A. / The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 6. pp. 1715-1725.
@article{bac14980241a45d2b7f9df8b4082dd11,
title = "The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation",
abstract = "We sought to determine the effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors. After LXT, baboons received no coagulation factors (historical control, n = 1), bolus administration of a human prothrombin concentrate complex (hPCC; 2.5 mL/kg, n = 2), continuous infusion of hPCC (1.0 mL/h, n = 1) or continuous infusion of human recombinant factor VIIa (1 µg/kg per hour, n = 3). The historical control recipient demonstrated persistent thrombocytopenia despite platelet administration after transplant, along with widespread thrombotic microangiopathy (TMA). In contrast, platelet levels were maintained in bolus hPCC recipients; however, these animals quickly developed large-vessel thrombosis and TMA, leading to graft failure with shortened survival. Recipients of continuous coagulation factor administration experienced either stabilization or an increase in their circulating platelets with escalating doses. Furthermore, transfusion requirements were decreased, and hepatic TMA was noticeably absent in recipients of continuous coagulation factor infusions compared with the historical control and bolus hPCC recipients. This effect was most profound with a continuous, escalating dose of factor VIIa. Further studies are warranted because this regimen may allow for prolonged survival following LXT.",
author = "N. Navarro-Alvarez and Shah, {J. A.} and A. Zhu and J. Ligocka and H. Yeh and N. Elias and I. Rosales and R. Colvin and Cosimi, {A. B.} and Markmann, {J. F.} and M. Hertl and Sachs, {D. H.} and Vagefi, {P. A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/ajt.13647",
language = "English (US)",
volume = "16",
pages = "1715--1725",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation

AU - Navarro-Alvarez, N.

AU - Shah, J. A.

AU - Zhu, A.

AU - Ligocka, J.

AU - Yeh, H.

AU - Elias, N.

AU - Rosales, I.

AU - Colvin, R.

AU - Cosimi, A. B.

AU - Markmann, J. F.

AU - Hertl, M.

AU - Sachs, D. H.

AU - Vagefi, P. A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - We sought to determine the effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors. After LXT, baboons received no coagulation factors (historical control, n = 1), bolus administration of a human prothrombin concentrate complex (hPCC; 2.5 mL/kg, n = 2), continuous infusion of hPCC (1.0 mL/h, n = 1) or continuous infusion of human recombinant factor VIIa (1 µg/kg per hour, n = 3). The historical control recipient demonstrated persistent thrombocytopenia despite platelet administration after transplant, along with widespread thrombotic microangiopathy (TMA). In contrast, platelet levels were maintained in bolus hPCC recipients; however, these animals quickly developed large-vessel thrombosis and TMA, leading to graft failure with shortened survival. Recipients of continuous coagulation factor administration experienced either stabilization or an increase in their circulating platelets with escalating doses. Furthermore, transfusion requirements were decreased, and hepatic TMA was noticeably absent in recipients of continuous coagulation factor infusions compared with the historical control and bolus hPCC recipients. This effect was most profound with a continuous, escalating dose of factor VIIa. Further studies are warranted because this regimen may allow for prolonged survival following LXT.

AB - We sought to determine the effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors. After LXT, baboons received no coagulation factors (historical control, n = 1), bolus administration of a human prothrombin concentrate complex (hPCC; 2.5 mL/kg, n = 2), continuous infusion of hPCC (1.0 mL/h, n = 1) or continuous infusion of human recombinant factor VIIa (1 µg/kg per hour, n = 3). The historical control recipient demonstrated persistent thrombocytopenia despite platelet administration after transplant, along with widespread thrombotic microangiopathy (TMA). In contrast, platelet levels were maintained in bolus hPCC recipients; however, these animals quickly developed large-vessel thrombosis and TMA, leading to graft failure with shortened survival. Recipients of continuous coagulation factor administration experienced either stabilization or an increase in their circulating platelets with escalating doses. Furthermore, transfusion requirements were decreased, and hepatic TMA was noticeably absent in recipients of continuous coagulation factor infusions compared with the historical control and bolus hPCC recipients. This effect was most profound with a continuous, escalating dose of factor VIIa. Further studies are warranted because this regimen may allow for prolonged survival following LXT.

UR - http://www.scopus.com/inward/record.url?scp=84978811081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978811081&partnerID=8YFLogxK

U2 - 10.1111/ajt.13647

DO - 10.1111/ajt.13647

M3 - Article

C2 - 26613235

AN - SCOPUS:84978811081

VL - 16

SP - 1715

EP - 1725

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -